Investment Rating - The report indicates a positive outlook for the CDMO industry, with expectations for improved order flow, revenue growth, and profit margins by 2026, particularly benefiting from the recovery of Chinese funding and increased demand for early projects [1][4]. Core Insights - The CDMO industry maintains a high overall profit margin, driven by the growing demand for emerging therapies and higher quality requirements from clients [2][4]. - Chinese CDMO companies are more aggressive in capacity expansion and new model investments, with capital expenditures accounting for approximately 22% of sales, while Indian companies adopt a more cautious approach [1][5]. - New trends in the CDMO industry include overseas expansion, automation, digital investments, and the development of peptide drugs and antibody-drug conjugates (ADCs) [1][6]. Summary by Sections Current Demand Situation - The global CDMO industry demand remains stable, supported by CMO projects and emerging therapies, with a notable focus on GLP-1, peptide capacity, and ADCs [2]. - Despite some pressures, overall profit margins are high due to increased demand for emerging therapies and quality assurance [2]. Investment Strategies - Chinese CDMO companies are proactive in expanding capacity and investing in new models, while Indian companies are more conservative, linking investments to visible market demand [5][12]. - Indian CDMO companies focus on geopolitical diversification and maintaining a good RFP/RFQ momentum, although the conversion of orders to actual financial results is slower than expected [8][11]. Future Market Outlook - R&D investments are expected to fluctuate in 2025, but most companies anticipate improvements in order flow, revenue growth, and profit margins by 2026, particularly due to the recovery of Chinese funding [4][15]. - The performance of Chinese companies is currently superior to that of Indian companies, with Indian firms expected to see financial results materialize by the 2026 fiscal year [11]. New Trends in the Industry - Key trends include overseas expansion, automation, digital investments, and advancements in peptide drugs and ADCs, with Chinese companies accelerating facility construction in response to geopolitical uncertainties [6][10]. - Companies like Samsung Biologics have begun operating their ADC capacity and have received significant orders from major global clients [6][10]. Geopolitical Factors - The impact of geopolitical factors on the CDMO industry has diminished, with normal business operations continuing without major disruptions [7][14]. - Some clients still consider potential disruptions from political factors, but technical strength and execution capabilities remain paramount [7]. Performance Comparison - In the peptide formulation sector, Chinese companies significantly outpace Indian firms in capacity, while Indian companies express optimism in the ADC field [10][11]. - The financial commercialization results for Indian companies are expected to lag behind those of Chinese companies, with growth rates projected to be in the mid-single digits for 2026 [11].

Core Insights - Targeted protein degradation technology has seen significant development in China, providing new strategies for treating diseases such as cancer, neurodegenerative diseases, and autoimmune diseases [1][8] - The market size for targeted protein degradation in China is projected to reach approximately 102 million yuan in 2024, reflecting a year-on-year growth of 112.50% [1][8] - The increasing demand for novel drugs is driven by an aging population and the rise of chronic diseases, highlighting the technology's potential to meet unmet clinical needs [1][8] Industry Overview - Targeted protein degradation involves hijacking cellular degradation mechanisms to specifically degrade target proteins, addressing diseases caused by protein accumulation or dysfunction [2][4] - The technology overcomes limitations of traditional small molecule inhibitors, enabling the targeting of "undruggable" proteins [2][4] Industry Development History - The industry has evolved over two decades, starting from basic research to global competition, with significant milestones including the introduction of PROTAC concepts and the establishment of early technology platforms [4][5] - Recent years have seen a surge in clinical trials and the establishment of a robust pipeline, with 35 clinical programs reported as of 2024 [4][5] Industry Value Chain - The upstream of the industry includes raw materials such as E3 ubiquitin ligase ligands and various production equipment [5][6] - The midstream focuses on research and development, while the downstream applications target oncology and neurodegenerative diseases [5][6] Key Companies and Performance - Leading companies in the PROTAC space include HaiChuang Pharmaceutical and KaiTou Pharmaceutical, with significant clinical advancements in prostate and breast cancer treatments [8][10] - Jiangsu Hengrui Medicine has adopted a "fast-follow + innovation" strategy, achieving a 22.63% increase in revenue in 2024 [10][11] Industry Trends - Continuous technological innovation is expected to break through core technical bottlenecks in PROTAC, molecular glue, and LYTAC/AUTAC technologies [12][13] - The market is expanding into rare disease applications, with targeted protein degradation strategies being developed for conditions like Alzheimer's disease [13] - The industry ecosystem is being restructured with deepening international collaborations, positioning China as a key player in global biopharmaceutical innovation [14]

Group 1 - UBS Group's long position in WuXi AppTec's H-shares decreased from 5.05% to 3.98% as of September 30 [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 478,226,490 | RMB | | 1 RMB | | 478,226,490 | | 增加 / 減少 (-) | | | 14,185,818 | | | RMB | | 14,185,818 | | 本月底結存 | | | 492,412,308 | RMB | | 1 RMB | | 492,412,308 | | 2. 股份分類 ...

致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 478,226,490 | RMB | | 1 RMB | | 478,226,490 | | 增加 / 減少 (-) | | | 14,185,818 | | | RMB | | 14,185,818 | | 本月底結存 | | | 492,412,308 | RMB | | 1 RMB | | 492,412,308 | | 2. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- ...

Core Viewpoint - The October stock market is expected to be influenced by the Federal Reserve's interest rate cuts, which may enhance market risk appetite and support economic recovery policies, leading to a focus on growth and value investment strategies in sectors like TMT, pharmaceuticals, and securities [1][3]. Group 1: Recommended Stocks - Stocks such as Zhaoyi Innovation, Luxshare Precision, and WuXi AppTec have received multiple recommendations from various brokerages, indicating strong market interest [1][3]. - Zhaoyi Innovation's stock price increased by 8.2% and WuXi AppTec by 6.42% as of September 30, reflecting positive market sentiment [3]. Group 2: Key Investment Themes - The focus remains on eight key sectors, including AI computing power, semiconductor self-sufficiency, solid-state batteries, commercial aerospace, and controllable nuclear fusion, which are expected to drive investment interest [3]. - The technology sector is anticipated to maintain its upward trend, with both domestic and overseas AI industries showing continuous improvement [3]. Group 3: Market Strategy Recommendations - Long-term strategies should consider high-growth and high-elasticity sectors such as communications, non-ferrous metals, gaming, and Hong Kong internet stocks [4]. - The market is advised to pay attention to sectors with improved fundamentals, particularly in non-banking areas, as well as to events that may catalyze market expectations, such as low-altitude economy and embodied intelligence [4].

Market Overview - In September, A-shares experienced significant volatility, with the Shanghai Composite Index attempting to breach 3900 points but failing, even dipping below 3800 points at times [1] - The performance varied across sectors, with technology growth sectors like semiconductors and AI showing strong activity, while traditional sectors like banking and non-bank financials lagged [1] - The Federal Reserve announced a 0.25 percentage point interest rate cut, the first of the year, which may attract foreign capital into the Hong Kong and A-share markets, enhancing market liquidity [1][2] Stock Recommendations - A total of 26 brokerages have released stock recommendations for October, covering 196 stocks, with a notable focus on the information technology sector [2][4] - Stocks like Zhaoyi Innovation, Luxshare Precision, and WuXi AppTec appeared most frequently in recommendations, with Zhaoyi Innovation being highlighted for its strong market position and recent performance [4][6] - The technology sector's stocks generally performed well in September, with several stocks increasing over 20%, while financial and consumer sectors underperformed [5][7] Economic Indicators - The People's Bank of China announced a release of 1.1 trillion yuan through open market operations and reverse repos, which is expected to boost market liquidity and support A-share performance post-holiday [2][6] - The anticipated "14th Five-Year Plan" and changes in capital market policies are expected to create investment opportunities [2][7] Sector Focus - Analysts suggest focusing on technology growth sectors, particularly those related to AI, smart manufacturing, and digital economy, as they are likely to benefit from recent market dynamics [2][8] - The performance of the Hang Seng Technology Index, which rose significantly, indicates a positive outlook for tech-related stocks in the A-share market [1][2] Future Outlook - Following the National Day holiday, A-shares are expected to continue a gradual upward trend, supported by strong performances in both US and Hong Kong markets during the holiday [1][2] - Analysts recommend monitoring the potential impact of further Federal Reserve rate cuts on market sentiment and foreign capital inflows [8][9]

Group 1 - UBS Group's short position in WuXi AppTec's H-shares increased from 1.95% to 3.55% as of September 29 [1]

Group 1 - The monthly "golden stocks" list reflects the comprehensive research strength and stock selection ability of various brokerages, with 111 stocks included as of October 1, 2023 [1] - Notable stocks attracting institutional attention this month include Hikvision, Stone Technology, Huayou Cobalt, Ecovacs, and Luoyang Molybdenum, with sectors like electronics, automotive, and pharmaceuticals receiving broker recognition [1][2] - Institutions believe that favorable factors for A-share performance are still in play, with expectations for the market center to rise in October due to technological industry catalysts and long-term policy layout windows [1][6] Group 2 - Hikvision, Stone Technology, Huayou Cobalt, Ecovacs, and Luoyang Molybdenum received recommendations from two brokerages each, including Everbright Securities and Guojin Securities [2][3] - The electronic sector, including stocks like Zhaoyi Innovation and SMIC, is favored by brokerages, with expectations for a strong performance in the fourth quarter due to traditional seasonal demand [4] - All 11 brokerage "golden stock" combinations have recorded positive returns year-to-date, with the top five being KSY Securities, Huaan Securities, Dongxing Securities, Everbright Securities, and China Galaxy [5] Group 3 - Institutions are optimistic about the "Red October" market, with catalysts for A-share performance continuing, and a potential upward shift in market structure expected [6] - Factors such as the calendar effect of the National Day holiday and the initiation of a Federal Reserve rate cut cycle are seen as supportive for market sentiment [6] - The liquidity outlook remains positive, with expectations for continued inflows into the market, and a structural rally may re-emerge after addressing short-term valuation issues [6]

Core Viewpoint - The October market is expected to continue a structural trend of "growth-oriented with cyclical support," driven by long-term policy support, intensive industrial catalysts, and a loose liquidity environment [1][6]. Group 1: Stock Recommendations - A total of 111 stocks have been included in the "golden stock" portfolios of 13 brokerage firms for October, with notable mentions including SMIC, WuXi AppTec, Huayou Cobalt, Hikvision, and Haier Smart Home [1][3]. - The most recommended stocks, each receiving two endorsements from different brokerages, include Zhaoyi Innovation, WuXi AppTec, Luoyang Molybdenum, Ecovacs, and SMIC, among others [4][3]. - The technology sector, particularly stocks like Zhaoyi Innovation, Datong Technology, and SMIC, is favored by brokerages, indicating a strong preference for TMT (Technology, Media, and Telecommunications) stocks [4][5]. Group 2: Market Outlook - Historical data shows that the A-share market typically experiences a rebound after the National Day holiday, with over 70% probability of an increase in the first week post-holiday [7]. - Multiple significant events are expected to occur in October, including the Federal Reserve's meeting and the release of Q3 reports, which could inject new vitality into the market [7][8]. - The technology growth sector is anticipated to present more opportunities in October, with expectations of a Federal Reserve rate cut boosting market sentiment [8].